Impact of nasal packing duration on sore throat after septorhinoplasty

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between the duration of nasal packing following septorhinoplasty surgery and the development of postoperative sore throat and pharyngitis. The research aims to understand how nasal packing affects swallowing and throat discomfort, which can lead to patient dissatisfaction. By analyzing the effects of different packing durations, the study seeks to identify potential interventions to improve patient outcomes and satisfaction post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ASA I and II patients
* aged from 20 to 40 years old
* undergo septorhinoplasty

Exclusion Criteria:

* Bleeding disorders
* Uncontrolled hypertension
* Cardiovascular diseases
* Uncontrolled diabetes mellitus
* Collagen disorders
* Pregnancy

Where it's running

• Neveen Kohaf
  Tanta, Egypt, Egypt Recruiting

Study contacts

• Principal investigator: Neveen Kohaf, ph.d — Al-Azhar University
• Study coordinator: Neveen Kohaf, Ph.D
• Email: nevenabdo@azhar.edu.eg
• Phone: +201060383012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Post-marketing follow-up of four devices for acute viral rhinitis and related conditions

  This study tests four medical devices (NS, NHE, NHG, and PIR) in real-life use to see if they are safe, tolerated, and helpful for people with acute viral rhinitis, rhinosinusitis, or rhinopharyngitis.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07383493

• Sublingual MM09 for dust-mite–triggered rhinitis and rhinoconjunctivitis in people aged 12–65 with or without mild-to-moderate asthma

  This trial will test whether daily sublingual MM09 reduces symptoms and the need for rescue medication in people aged 12–65 who have rhinitis or rhinoconjunctivitis caused by dust mites, with or without mild-to-moderate asthma.

  Recruiting at 14 sites Phase 3 Inmunotek S.L. · Nueve de Julio, Buenos Aires and 18 other locations · NCT07348302

• Mannan-Conjugated Allergoids for House Dust M mite Allergy

  A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.

  Recruiting at 2 sites Phase 3 Inmunotek S.L. · Covilha, Castelo Branco District and 15 other locations · NCT07904195

• Mannan-conjugated Allergoids for House Dust Mite Allergy

  A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.

  Recruiting at 4 sites Phase 3 Inmunotek S.L. · Coimbra and 15 other locations · NCT07904052

• Dog-allergy immunotherapy with Alutard SQ Dog in Swedish practice

  This study tests whether Alutard SQ Dog immunotherapy helps adults with moderate-to-severe dog allergy when used in real-world Swedish care.

  Recruiting at 2 sites Phase 4 Karolinska Institutet · Lund, Skåne County and 1 other locations · NCT07651891

• PL-14 Allergy Blocker vs saline spray for seasonal nasal allergies

  This study tests whether PL-14 Allergy Blocker, a drug-free nasal gel, reduces nasal allergy symptoms in adults with seasonal allergic rhinitis compared with saline spray.

  Recruiting at 4 sites Polyrizon Ltd. · Normal, Illinois and 4 other locations · NCT07588672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.